Why Testosterone Cypionate Causes Fertility Suppression: The Mechanism Explained

Where testosterone cypionate enters the loop

The hypothalamus releases gonadotropin-releasing hormone in pulses, which signal the pituitary to release LH and FSH. LH prompts Leydig cells in the testes to make testosterone; FSH supports the Sertoli cells that nurse developing sperm. Testosterone circulating in the blood feeds back on the hypothalamus and pituitary and slows their output, the body's own brake on testicular production.

Testosterone cypionate is an oil-soluble ester of testosterone. Injected into muscle, it is absorbed slowly from the oil depot and split to free testosterone. The Depo-Testosterone label gives a half-life of about 8 days after intramuscular injection and a usual dose of 50 to 400 mg every 2 to 4 weeks, and says the slow absorption from the oil is what allows a 2 to 4 week interval [1].

What the label says the injection does to LH and FSH

The Depo-Testosterone label states that during exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary LH, and that at large doses of exogenous androgens spermatogenesis may also be suppressed through feedback inhibition of pituitary FSH [1].

The block sits at the pituitary: LH falls because the pituitary releases less of it, and the testes lose the signal that tells them to make their own testosterone [1].

The FSH effect is dose-linked in the label's own wording, 'at large doses' [1]. The adverse reactions section puts it in clinical terms: oligospermia may occur at high dosages [1]. The drug abuse section lists testicular atrophy, subfertility and infertility among reactions reported in men who abuse anabolic steroids [1]. The Azmiro (cypionate) and Xyosted (enanthate) labels add that reduced fertility is seen in some men on testosterone replacement and that the effect on fertility may be irreversible.

Serum testosterone and sperm production are different measures

Sperm production depends on testosterone made locally in the testis by Leydig cells under LH drive. The label describes endogenous testosterone release being inhibited by LH feedback while exogenous androgen is given [1]. A serum testosterone in the normal range on treatment therefore includes the injected hormone, and it does not by itself show how the testes are producing sperm. A semen analysis measures that directly.

Recovery after stopping

The clearest timing data come from hormonal male contraception research, which used testosterone to suppress sperm on purpose. An integrated analysis of 30 studies pooled 1,549 healthy men with normal testosterone who used androgen or androgen-progestin regimens. Median time for sperm concentration to recover to 20 million/mL was 3.4 months; 67% were back to that threshold within 6 months, 90% within 12 months, 96% within 16 months and 100% within 24 months. Recovery was faster with shorter-acting testosterone preparations, shorter treatment, higher baseline sperm counts and, in that cohort, older age [2]. Those men did not have hypogonadism, so the numbers describe recovery from deliberate hormonal suppression rather than recovery in men treated for low testosterone.

A second dataset comes from men who were actually infertile after testosterone use. In a retrospective series of 66 men, testosterone was stopped and high-dose hCG plus a selective estrogen receptor modulator was given. A total motile count above 5 million was reached by 46 men (70%) within 12 months. Only 64.8% of men who started azoospermic got there, versus 91.7% of men who started with cryptozoospermia, and older age and longer testosterone use predicted slower recovery [3].

The two analyses point in opposite directions on age: older age predicted faster recovery in the contraception cohort [2] and slower recovery in the infertility series [3]. The populations and the endpoints differ, so neither should be read as a rule for an individual man.

hCG after testosterone-associated infertility

Human chorionic gonadotropin binds the same Leydig cell receptor as LH, so it can drive testicular testosterone production even when pituitary LH is suppressed. In a retrospective case series of 49 men who had azoospermia or severe oligospermia (under 1 million/mL) while on exogenous testosterone, treatment with hCG 3,000 units subcutaneously every other day plus clomiphene, tamoxifen, anastrozole or recombinant FSH returned or improved spermatogenesis in 47 men (95.9%), at an average of 4.6 months, with a mean first sperm density of 22.6 million/mL. Recovery did not differ by the type of testosterone used [5]. The series had no control group and its abstract does not say whether testosterone was continued during treatment.

What the guidance says before starting

The Endocrine Society's 2018 clinical practice guideline recommends against starting testosterone therapy in men who are planning fertility in the near term [4].